Detailed long-term dynamics of neutrophil-to-lymphocyte ratio under biologic treatment reveal differential effects of tumour necrosis factor-alpha and interleukin 12/23 antagonists

• Verfasst von: Hoffmann, Jochen [VerfasserIn]
• Verfasst von: Knoop, Christian [VerfasserIn]
• Verfasst von: Enk, Alexander [VerfasserIn]
• Verfasst von: Hadaschik, Eva [VerfasserIn]
• Titel: Detailed long-term dynamics of neutrophil-to-lymphocyte ratio under biologic treatment reveal differential effects of tumour necrosis factor-alpha and interleukin 12/23 antagonists
• Verf.angabe: Jochen H.O. Hoffmann, Christian Knoop, Alexander H. Enk and Eva N. Hadaschik
• E-Jahr: 2021
• Jahr: Sep 30, 2021
• Umfang: 5 S.
• Fussnoten: Gesehen am 06.04.2022
• Titel Quelle: Enthalten in: Acta dermato-venereologica
• Ort Quelle: Uppsala : Acta Dermato-Venereologica, 1946
• Jahr Quelle: 2021
• Band/Heft Quelle: 101(2021), 10, Artikel-ID adv00568, Seite 1-5
• ISSN Quelle: 1651-2057
• DOI: doi:10.2340/actadv.v101.271
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: adalimumab
• Sach-SW: biomarker
• Sach-SW: cardiovascular disease
• Sach-SW: etanercept
• Sach-SW: psoriasis
• Sach-SW: ustekinumab
• K10plus-PPN: 179741156X

Abstract

Psoriasis is thought to be associated with a reduced life expectancy through systemic inflammation. A comparative, retrospective analysis of neutrophil-to-lympho-cyte ratio, a biomarker of systemic inflammation and cardiovascular risk, under 196 treatments with tumour necrosis factor-α and interleukin-12/23 antagonists was performed. Neutrophil-to-lympho-cyte ratio decreased significantly within 3 months of initiation of treatment and remained stable at reduced levels for at least 33 months. Dynamics were more pronounced and neutrophil-to-lympho-cyte ratio under treatment was lower in patients treated with tumour necrosis factor-α compared with interleukin-12/23 antagonists (geometric mean (95% confidence interval): 2.03 (1.9, 2.1) vs 2.63 (2.2, 3.2), respectively, p = 0.014). tumour necrosis factor-α antagonist treatment and baseline neutrophil-to-lympho-cyte ratio were independent predictors of a median low cardiovascular risk neutrophil-to-lympho-cyte ratio (< 2.15) during treatment (odds ratio (95% confidence interval): 0.53 (0.4-0.8) and 4.68 (1.0-19.1), p = 0.001 and p = 0.032, respectively). These results demonstrate a rapid and sustained reduction in biomarkers of systemic inflammation under biologic treatment. Furthermore, these data suggest class-specific effects on systemic inflammation, which may be relevant for the prevention of psoriasis co-morbidity by systemic treatment.